Sign In
Buy VRTX
$441.74
+13.40 (+3.13%)
At Close: Jun 04, 2026
Why Vertex Stock Is Soaring Today
02:08pm, Wednesday, 13'th Dec 2023
Vertex Pharmaceuticals' NaV1.8-inhibitor VX-548 measurably reduces peripheral neuropathic pain among diabetics. The drug, however, can be used to treat similar pain stemming from other health conditio
Stock Movers: J&J, Vertex Pharma and Tesla
01:05pm, Wednesday, 13'th Dec 2023
The “Halftime Report” Investment Committee debate the market movers they own.
Vertex shares pop after non-opioid painkiller posts positive mid-stage trial results
01:05pm, Wednesday, 13'th Dec 2023
The results support Vertex's hopes of developing a drug that can provide strong pain relief without the addictive potential of opioid medications.
Midday Movers: Vertex Surges on Gene-Editing Deal, Pfizer Falls on Guidance Miss
12:55pm, Wednesday, 13'th Dec 2023
U.S. equities were slightly higher at midday ahead of comments from the Federal Reserve following its last meeting of the year. It's expected the central bank won't raise interest rates any further to
Next Wave Biotech: 3 Stocks Poised for Breakthrough Success
12:04pm, Wednesday, 13'th Dec 2023
The pandemic pushed major biotech stocks into the spotlight as vaccine demands rose to unprecedented highs. Investors flocked to the industry in the next few years after the COVID-19 breakout.
Vertex's stock heads for all-time high as non-opioid painkiller shows promise
12:03pm, Wednesday, 13'th Dec 2023
Vertex Pharmaceuticals Inc. shares VRTX, +10.68% were on track for an all-time high Wednesday after the company released new data from a trial of its investigational non-opioid pain medicine.
Better Growth Stock: Vertex Pharmaceuticals or Exact Sciences?
08:45am, Wednesday, 13'th Dec 2023
Healthcare stocks rarely outperform the S&P 500 over long periods. Exact Sciences and Vertex Pharmaceuticals have been two of the rare exceptions over the prior 10 years.
BLUE, CRSP & VRTX Down Despite FDA Nod to SCD Therapies
01:32pm, Monday, 11'th Dec 2023
The FDA approves two one-time gene therapies for treating sickle cell disease. One of them utilizes the Nobel prize-winning CRISPR/Cas9 gene-editing technology.
Vertex Pharmaceuticals Just Proved Something Big to Investors. Time to Buy?
05:45am, Sunday, 10'th Dec 2023
Vertex and partner CRISPR Therapeutics just won FDA approval for blood disorders treatment exa-cel -- to be commercialized as Casgevy. Vertex is known for its cystic fibrosis drugs, which bring in bil
The FDA just approved the first gene editing therapy for sickle cell anemia, but it'll cost $2.2 million per person
03:12pm, Saturday, 09'th Dec 2023
The FDA approved the first gene therapies for sickle cell anemia. The two approved treatments, Casgevy and Lyfgenia, will cost $2.2 million and $3.1 million.
Forget the "Magnificent Seven": Buy This Stock Instead
10:07am, Saturday, 09'th Dec 2023
The "Magnificent Seven" are all great stocks to own, but none has an actual monopoly in its field. Vertex Pharmaceuticals does have a monopoly in selling certain medicines critical to patients' health
2 Superior Growth Stocks Up 23% and 105% in 2023 to Buy Now and Hold for Years
09:36am, Saturday, 09'th Dec 2023
The healthcare and e-commerce industries continue to generate substantial levels of consumer spending. Vertex Pharmaceuticals just marked another landmark approval, which could be the first of multipl
Vertex And CRISPR Therapeutics: Historic Exa-cel Approval, Why Market Is Nonplussed
08:06pm, Friday, 08'th Dec 2023
The FDA has granted approval to a CRISPR-based gene editing therapy for the first time in history, validating the approach. The therapy, called Casgevy, is approved to treat Sickle Cell Disease after
Vertex, CRISPR Therapeutics Get FDA Approval for First CRISPR Gene-Editing Therapy in US
05:25pm, Friday, 08'th Dec 2023
Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP) announced Friday that the Food and Drug Administration (FDA) gave them approval for use of the first-ever gene-editing therapy using CRISPR
Patients describe Casgevy gene-editing treatment as a cure, says Vertex CEO Reshma Kewalramani
03:45pm, Friday, 08'th Dec 2023
Reshma Kewalramani, CEO of Vertex Pharmaceuticals, and CNBC's Angelica Peebles join 'Power Lunch' to discuss the latest FDA gene-editing treatment approval, drug pricing, and more.
